{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:06:06Z","timestamp":1762956366031,"version":"3.37.3"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32AR048522"],"award-info":[{"award-number":["T32AR048522"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1136\/annrheumdis-2020-217690","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T21:25:37Z","timestamp":1590096337000},"page":"1386-1388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5045-5255","authenticated-orcid":false,"given":"Maximilian F","family":"Konig","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4074-0516","authenticated-orcid":false,"given":"Alfred HJ","family":"Kim","sequence":"additional","affiliation":[]},{"given":"Marc H","family":"Scheetz","sequence":"additional","affiliation":[]},{"given":"Elizabeth R","family":"Graef","sequence":"additional","affiliation":[]},{"given":"Jean W","family":"Liew","sequence":"additional","affiliation":[]},{"given":"Julia","family":"Simard","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M","family":"Machado","sequence":"additional","affiliation":[]},{"given":"Milena","family":"Gianfrancesco","sequence":"additional","affiliation":[]},{"given":"Jinoos","family":"Yazdany","sequence":"additional","affiliation":[]},{"given":"Daman","family":"Langguth","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3156-3418","authenticated-orcid":false,"given":"Philip C","family":"Robinson","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2020-217690_bib1","unstructured":"AHJ K, Sparks JA, Liew JW, et al. A rush to judgment? rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. Ann Intern Med 2020:M20\u20131223."},{"key":"10.1136\/annrheumdis-2020-217690_bib2","unstructured":"Lane JCE, Weaver J, Kostka K, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. Rheumatology 2020."},{"key":"10.1136\/annrheumdis-2020-217690_bib3","doi-asserted-by":"crossref","unstructured":"Roden DM, Harrington RA, Poppas A, et al. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. J Am Coll Cardiol 2020. doi: doi:10.1016\/j.jacc.2020.04.016. [Epub ahead of print: 09 Apr 2020].http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32283123","DOI":"10.1161\/CIRCULATIONAHA.120.047521"},{"key":"10.1136\/annrheumdis-2020-217690_bib4","doi-asserted-by":"crossref","unstructured":"Chorin E, Dai M, Shulman E, et al. The QT interval in patients with SARS-CoV-2 infection treated with Hydroxychloroquine\/Azithromycin. Cardiovascular Medicine 2020.","DOI":"10.1101\/2020.04.02.20047050"},{"key":"10.1136\/annrheumdis-2020-217690_bib5","doi-asserted-by":"crossref","unstructured":"Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Epidemiology 2020.","DOI":"10.1101\/2020.03.22.20040758"},{"key":"10.1136\/annrheumdis-2020-217690_bib6","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1136\/annrheumdis-2020-217506","article-title":"Sle, hydroxychloroquine and NO SLE patients with COVID-19: a comment","volume":"79","author":"Joob","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2020-217690_bib7","unstructured":"Remarks by President Trump, Vice President Pence, and Members of the Coronavirus Task Force in Press Briefing. The white house. Available: https:\/\/www.whitehouse.gov\/briefingsstatements\/remarks-president-trump-vice-president-pence-members-coronavirus-task-forcepress-briefing-19\/ [Accessed 24 Apr 2020]."},{"key":"10.1136\/annrheumdis-2020-217690_bib8","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1136\/annrheumdis-2020-217524","volume":"2020","author":"Monti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2020-217690_bib9","doi-asserted-by":"crossref","unstructured":"Gianfrancesco MA, Hyrich KL, Gossec L, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology alliance provider registries. Lancet Rheumatol 2020:S2665991320300953. doi:10.1016\/S2665-9913(20)30095-3, http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32309814","DOI":"10.1016\/S2665-9913(20)30125-9"},{"key":"10.1136\/annrheumdis-2020-217690_bib10","unstructured":"Mathian A, Mahevas M, Rohmer J, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheumat Dis 2020. [Epub ahead of print: 24 Apr 2020]."},{"key":"10.1136\/annrheumdis-2020-217690_bib11","unstructured":"Search of: Recruiting, Completed Studies | COVID | Hydroxychloroquine - List Results - ClinicalTrials.gov. Available: https:\/\/clinicaltrials.gov\/ct2\/results?cond=COVID&intr=Hydroxychloroquine&Search=Apply&re crs=a&recrs=e&age_v=&gndr=&type=&rslt= [Accessed 19 Apr 2020]."},{"key":"10.1136\/annrheumdis-2020-217690_bib12","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"key":"10.1136\/annrheumdis-2020-217690_bib13","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1136\/annrheumdis-2020-217690_bib14","doi-asserted-by":"crossref","unstructured":"Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020:ciaa237. doi:10.1093\/cid\/ciaa237, http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32150618","DOI":"10.1093\/cid\/ciaa237"},{"key":"10.1136\/annrheumdis-2020-217690_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"10.1136\/annrheumdis-2020-217690_bib16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fphar.2014.00174","article-title":"Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of biomedical research","volume":"5","author":"Tuntland","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1136\/annrheumdis-2020-217690_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/095632020601700505","article-title":"Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB\/c mice","volume":"17","author":"Barnard","year":"2006","journal-title":"Antivir Chem Chemother"},{"key":"10.1136\/annrheumdis-2020-217690_bib18","unstructured":"CENTER FOR DRUG EVALUATION AND RESEARCH. APPLICATION NUMBER:021246Orig1s045 and 021087Orig1s062 [Abstracted from NDA 21087\/S-062 Clinical Review, T. Vargas-Kasambira]. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/021246Orig1s045_021087Orig1s%20062SumR.pdf [Accessed 19 Apr 2020]."},{"key":"10.1136\/annrheumdis-2020-217690_bib19","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1128\/AAC.02440-12","article-title":"Pharmacokinetic-Pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies","volume":"57","author":"Rayner","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1136\/annrheumdis-2020-217690_bib20","doi-asserted-by":"crossref","unstructured":"Arnold SL, Buckner F. Hydroxychloroquine for treatment of SARS-CoV-2 infection? improving our confidence in a model-based approach to dose selection. Clin Transl Sci 2020. doi: doi:10.1111\/cts.12797. [Epub ahead of print: 08 Apr 2020].http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32268005","DOI":"10.1111\/cts.12797"},{"key":"10.1136\/annrheumdis-2020-217690_bib21","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.41121","article-title":"Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy","volume":"72","author":"Petri","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/annrheumdis-2020-217690_bib22","doi-asserted-by":"crossref","unstructured":"Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an openlabel, randomized, controlled trial. Infectious Diseases 2020. doi:https:\/\/doi.org\/10.1101\/2020.04.10.20060558","DOI":"10.1101\/2020.04.10.20060558"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724012135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724012135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2020-217690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T06:05:06Z","timestamp":1737439506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724012135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0003496724012135"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2020-217690","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2020-217690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 \u00a9 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}